CDR2L

Across TCGA pan-cancer cohorts, CDR2L RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CDR2L data layer compared with 3 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CDR2L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDR2L expression acts as an unfavorable survival marker, although some lineages such as KIRC and DLBC show a favorable association.

ACC, MESO, and COAD are the cancer types where CDR2L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.276	0.614	<.001	95	view →
MESO	DFS	Median	All	0.267	0.457	<.001	75	view →
COAD	DFS	Quartile	IV	0.242	0.683	<.001	67	view →
HNSC	DFS	Median	All	0.551	0.761	<.001	51	view →
BLCA	OS	Median	All	0.224	0.541	.004	45	view →
LGG	OS	Median	All	0.748	0.870	<.001	43	view →
UVM	OS	Quartile	II,III,IV	0.597	0.950	.011	36	view →
KIRP	OS	Tertile	III,IV	0.354	0.730	.011	35	view →
KIRC	DFS	Median	IV	0.619	0.296	.009	33	view →
LUAD	OS	Quartile	All	0.574	0.740	.005	18	view →
PAAD	DFS	Tertile	All	0.200	0.455	.009	16	view →
DLBC	OS	Median	III,IV	1.000	0.328	.018	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CDR2L–ACC (DFS)

Open the ACC breakdown →